Bempedoic Acid And Ezetimibe

Introduction Overview

Generic Name

bempedoic acid and ezetimibe

Brand Name

Nexlizet

Dosage Form

oral tablets

Drug Class

Antihyperlipidemic combinations

Pharmacokinetics

Absorption:
Nexlizet, containing bempedoic acid and ezetimibe, is administered orally in tablet form. Both components are absorbed through the gastrointestinal tract, with ezetimibe showing rapid absorption and bioavailability after oral intake. Bempedoic acid achieves peak plasma concentrations typically several hours post-dose. Food does not significantly affect the absorption of Nexlizet, allowing administration with or without meals. The ezetimibe component undergoes enterohepatic recirculation, extending its presence in circulation and maintaining its cholesterol absorption inhibition. Clinical studies demonstrate consistent and predictable absorption profiles, which facilitate once-daily dosing for sustained lipid-lowering effects.

Distribution:
Bempedoic acid exhibits moderate plasma protein binding, primarily to albumin, which influences its distribution in the body. Ezetimibe shows extensive plasma protein binding (>90%) and distributes widely in tissues relevant to cholesterol metabolism, including the intestine and liver. Bempedoic acid's distribution ensures effective delivery to the liver, the site of its primary pharmacological action. The volume of distribution for both agents supports their targeted activity with limited peripheral tissue accumulation. This distribution profile minimizes systemic exposure and adverse effects. Clinical pharmacology assessments have shown that bempedoic acid is converted to its active Coenzyme A (CoA) form in the liver, enhancing its local action.

Metabolism:
Bempedoic acid is a prodrug that is activated in the liver by very-long-chain acyl-CoA synthetase-1 to its active moiety, bempedoyl-CoA, which inhibits ATP citrate lyase (ACL). This hepatic activation limits exposure of peripheral tissues, reducing muscle-related side effects. Ezetimibe is extensively metabolized in the intestinal wall and liver to its active glucuronide metabolite via UDP-glucuronosyltransferase enzymes (UGT1A1 and UGT1A3). Both parent and glucuronide forms contribute to therapeutic effects by inhibiting cholesterol absorption. Metabolic pathways show minimal involvement of cytochrome P450 enzymes, lowering the potential for CYP-mediated drug interactions.

Elimination:
The elimination of bempedoic acid occurs primarily through renal excretion of metabolites and biliary-fecal routes, with an elimination half-life conducive to once-daily administration. Ezetimibe and its glucuronide conjugate are eliminated mainly via biliary secretion into feces. Renal excretion of unchanged ezetimibe is minimal. The enterohepatic recycling of ezetimibe prolongs its therapeutic presence. Dose adjustments of Nexlizet are generally not required in mild to moderate renal or hepatic impairment; however, safety in severe hepatic or renal dysfunction has not been established. Clinical trials have shown steady-state concentrations are achieved within 7 days of dosing, supporting the established dosing regimen.

Dosage Forms

Available Dosage Forms:
Nexlizet is available as a single oral tablet dosage form, each tablet containing 180 mg of bempedoic acid and 10 mg of ezetimibe. The tablet is coated and designed for once-daily administration, with a size and coating facilitating patient adherence.

Dosages for Adults and Adolescents:
The recommended adult dose of Nexlizet is one 180-10 mg tablet taken orally once daily. The tablet should be swallowed whole and may be taken with or without food. There is no approved pediatric dosage, and the safety and efficacy in patients under 18 years have not been established. The dosage may be used alone or added to other lipid-lowering therapies, including statins, to achieve LDL-C reduction.

Specific Patient Populations:
Nexlizet dosage does not require adjustment in patients with mild to moderate hepatic or renal impairment. Its safety has not been rigorously studied in populations with severe liver dysfunction or end-stage renal disease requiring dialysis. Use in geriatric populations is supported by clinical data, but careful monitoring is advised, especially because of higher risk for tendon injury. Pregnant or breastfeeding women should use Nexlizet only if clearly needed, due to potential fetal harm and unknown excretion in breast milk. Patients with a history of gout or tendon disorders require cautious use and close monitoring.

Clinical Guidelines:
Nexlizet is prescribed as an adjunct to diet to reduce elevated LDL cholesterol levels in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). It may be used alone or in combination with maximally tolerated statin therapy, particularly in individuals who cannot achieve LDL-C goals or who are statin intolerant. Timing of doses relative to bile acid sequestrants is important; Nexlizet should be taken at least 2 hours before or 4 hours after bile acid binding agents to avoid reduced absorption.

Mechanism Of Action

Nexlizet combines two agents with complementary mechanisms to lower low-density lipoprotein cholesterol (LDL-C). The bempedoic acid component acts as a prodrug, which upon hepatic activation inhibits ATP citrate lyase (ACL), a key enzyme in the cholesterol biosynthesis pathway upstream of HMG-CoA reductase. By blocking ACL, bempedoic acid reduces the production of acetyl-CoA, the building block for cholesterol synthesis, effectively decreasing the hepatic cholesterol pool. This inhibition leads to upregulation of LDL receptors on hepatocyte surfaces, enhancing clearance of circulating LDL particles and thereby lowering plasma LDL-C levels.

The ezetimibe component acts at the intestinal level by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein, which is responsible for the intestinal absorption of dietary and biliary cholesterol. By blocking NPC1L1, ezetimibe reduces the cholesterol delivered to the liver, further decreasing the hepatic cholesterol content. This complementary action supports the LDL receptor upregulation induced by bempedoic acid, synergistically enhancing LDL-C reduction.

Together, Nexlizet’s dual action targets cholesterol homeostasis both by reducing endogenous cholesterol synthesis in the liver and limiting exogenous cholesterol absorption from the intestine. This dual mechanism enhances LDL-C lowering efficacy beyond that achieved by either agent alone or by statins alone. Clinical trials have demonstrated that when added to maximally tolerated statin therapy, Nexlizet significantly reduces LDL-C levels, with an average reduction of approximately 38% after 12 weeks of treatment.

From a biochemical perspective, bempedoic acid’s liver-selective activation limits systemic exposure, reducing muscle tissue inhibition and thus decreasing the risk of muscle-related side effects commonly associated with statins. Ezetimibe’s site-specific action and lack of effect on CYP450 enzymes make it a well-tolerated agent with minimal drug-drug interactions. Collectively, the mechanisms make Nexlizet a valuable therapy for patients with hyperlipidemia who are statin-intolerant or require additional LDL-C lowering.

Pharmacological Actions

Inhibits ATP citrate lyase (ACL) enzyme, reducing hepatic cholesterol biosynthesis upstream of HMG-CoA reductase.
Selective inhibition of intestinal cholesterol absorption via blockade of the NPC1L1 transporter by ezetimibe.
Upregulation of hepatic LDL receptors, increasing clearance of circulating LDL cholesterol.
Dual-action antihyperlipidemic effect resulting in significant LDL-C lowering.
Liver-specific prodrug activation limits muscle exposure, reducing risk of myopathy compared to statins.
Reduces total cholesterol and apolipoprotein B levels.
Exhibits additive LDL-C lowering effect when combined with statins and other lipid-lowering agents.
Does not affect triglycerides or high-density lipoprotein cholesterol (HDL-C) significantly.
Minimal involvement of cytochrome P450 enzymes, reducing potential for drug interactions.
Modulates cholesterol homeostasis to reduce cardiovascular risk in adults with hyperlipidemia.
May reduce inflammatory biomarkers associated with atherosclerosis.
Demonstrates improvement in lipid parameters in patients with heterozygous familial hypercholesterolemia (HeFH).
Facilitates use in statin-intolerant patients or those unable to achieve LDL-C targets with statins alone.
Exhibits a synergistic effect complementing dietary cholesterol reduction strategies.

Therapeutic Or Clinical Uses

Treatment of primary hyperlipidemia to reduce elevated LDL cholesterol levels in adults.
Management of heterozygous familial hypercholesterolemia (HeFH) in adults.
Adjunct therapy to diet to improve LDL-C lowering when statin therapy is insufficient or not tolerated.
Reduction of cardiovascular events risk associated with high LDL cholesterol levels.
Use in patients with or at high risk for cardiovascular disease who require additional LDL-C reduction.
Alternative or concomitant therapy in statin-intolerant patients.
Combination product to target both endogenous cholesterol synthesis and exogenous absorption.
Reduction of total cholesterol and apolipoprotein B alongside LDL-C.
Adjunct treatment in combination with other lipid-lowering agents such as statins, fibrates, or bile acid sequestrants.
Potential role in reducing risk of myocardial infarction and coronary revascularization procedures.
Supported for use in patients unable to achieve LDL-C goals with lifestyle changes alone.
Utilized to complement dietary modifications for comprehensive hyperlipidemia management.
Recommended for patients requiring an additional mechanism of LDL-C reduction beyond statins.
May play a role in reducing inflammation markers related to atherosclerosis.

Side Or Adverse Effects

Common cold symptoms, flu, or flu-like symptoms.
Back pain, which may be mild to moderate.
Bronchitis or other types of lung infections.
Anemia due to low red blood cell levels.
Increased serum uric acid levels, potentially leading to gout.
Diarrhea and gastrointestinal discomfort including stomach pain.
Muscle spasms or pain, though less frequent than with statins.
Pain localized to shoulders, legs, or arms.
Elevations of liver enzymes indicating potential hepatocellular stress.
Fatigue or tiredness occurring in a small proportion of patients.
Rare but serious tendon injury or tendon rupture, particularly in older adults or those on corticosteroids or fluoroquinolones.
Hypersensitivity reactions including rash, urticaria, angioedema, and anaphylaxis related to ezetimibe component.
Potential allergic reactions such as swelling of face, lips, mouth, or tongue.
Possible increased risk for tendon rupture within weeks to months of therapy initiation.
Gout exacerbation in patients with prior gout history or elevated uric acid.

Precautions

Monitor serum uric acid levels regularly to detect hyperuricemia early.
Use caution in patients with a history of gout or hyperuricemia.
Assess patients for history of tendon disorders, as risk of tendon rupture is elevated.
Avoid or closely monitor Nexlizet use with concurrent fluoroquinolone or corticosteroid therapy.
Patients over 60 years of age have increased risk of tendon injury and should be monitored closely.
Discontinue Nexlizet promptly if signs of tendon rupture or severe tendon injury occur.
Use cautiously in patients with moderate to severe hepatic impairment.
Not recommended in patients with severe renal impairment or end-stage renal disease on dialysis due to lack of safety data.
Avoid use in pregnancy because of potential risk of fetal harm; effective contraception is advised.
Reassess therapy in breastfeeding women due to unknown excretion in human milk.
Inform patients to report symptoms of muscle pain, weakness, or unusual joint pain immediately.
Check for potential drug-drug interactions prior to starting therapy.
Educate patients on recognizing signs of allergic reactions and instruct to seek immediate care if symptoms appear.
Advise patients on proper timing of Nexlizet administration relative to bile acid sequestrant drugs.
Regularly monitor liver function tests during therapy, especially in patients with pre-existing liver conditions.

Warnings

May cause increased blood uric acid levels leading to gout attacks, especially in patients with prior history of gout.
Risk of tendon rupture or injury, which may occur within weeks or months of therapy initiation.
Tendon rupture risk is higher in patients older than 60 years, those on corticosteroids or fluoroquinolone antibiotics, and in patients with renal failure or a history of tendon disorders.
Allergic reactions including anaphylaxis, angioedema, rash, and urticaria may develop from the ezetimibe component.
Avoid use in patients with known hypersensitivity to bempedoic acid, ezetimibe, or any ingredients in Nexlizet.
Potential hepatotoxicity indicated by elevated liver enzymes; monitor liver function tests during treatment.
May cause harm to an unborn baby; effective contraception recommended during treatment.
Not recommended during breastfeeding due to unknown excretion and potential effects on the infant.
Patients should be educated to stop the medication and seek medical attention immediately if symptoms of tendon rupture or severe hypersensitivity occur.
Use with caution in patients with moderate to severe liver impairment.
Potential drug interactions with simvastatin and pravastatin may increase risk of muscle-related adverse effects.
Discontinue therapy if serious adverse reactions, including tendon rupture or severe hypersensitivity, occur.
The safety and efficacy of Nexlizet in children under 18 have not been established.
Overdose symptoms have not been well characterized; in case of overdose, contact poison control center or emergency services immediately.
Consider alternative lipid-lowering therapies if patient develops intolerable adverse effects.

Contraindication

Known hypersensitivity to bempedoic acid.
Known hypersensitivity to ezetimibe or any component of the tablet formulation.
History of allergic reactions to Nexlizet ingredients.
Severe hepatic impairment due to lack of safety and efficacy data.
Severe renal impairment including patients on dialysis, as safety in these populations is unestablished.
Pediatric patients younger than 18 years old due to unestablished safety and efficacy.
Patients with active tendinopathy or tendon rupture at initiation of therapy.
Concomitant use with other agents contraindicated due to increased risk of muscle injury without close medical supervision.
Pregnant women unless potential benefits justify risks due to possible fetal harm.
Known hypersensitivity to any inactive ingredients in the tablet such as lactose or dyes included in tablet coating.
Patients with prior severe hypersensitivity reactions to combining antihyperlipidemic agents containing either component.
Use not recommended in breastfeeding women without risk-benefit assessment.
Patients with untreated hypothyroidism should be stabilized prior to initiation to minimize risk of adverse effects.
Patients currently experiencing acute gout attacks until controlled.
Concurrent use with statins that are contraindicated or with history of statin intolerance without medical supervision.

Drug Interactions

Increased risk of myopathy or muscle pain when concomitantly used with simvastatin or pravastatin.
Potential interactions with cyclosporine, which may alter plasma concentrations of components leading to altered efficacy or toxicity.
Fibrates (such as gemfibrozil) co-administration may enhance adverse muscle effects; risk assessment warranted.
Bile acid sequestrants like cholestyramine or colesevelam may reduce absorption of ezetimibe; dose Nexlizet at least 2 hours before or 4 hours after these agents.
Concurrent use with fluoroquinolone antibiotics may increase the risk of tendon rupture.
Corticosteroids may potentiate tendon injury risk when combined with Nexlizet.
Minimal cytochrome P450 interactions; however, monitor for unknown interactions especially with drugs affecting glucuronidation pathways.
May modestly affect metabolism of certain drugs processed via UDP-glucuronosyltransferase enzymes.
Potential for altered efficacy when combined with other lipid-lowering therapies, requiring monitoring of lipid profile.
Concurrent use with drugs affecting renal function may influence elimination profile of bempedoic acid.
Unknown interaction with other cardiovascular medications; clinical monitoring advised.
No significant interaction reported with antihypertensive agents or oral antidiabetics.
Interaction potential with supplements and herbal products is not well characterized; advise caution.
Patients should inform healthcare providers about all medications, including over-the-counter and herbal products, to evaluate potential interactions.
Therapeutic drug monitoring may be considered in polypharmacy or in patients with comorbidities.

Preparations Of The Drug

Nexlizet comes as a film-coated oral tablet containing a fixed-dose combination of 180 mg bempedoic acid and 10 mg ezetimibe.
Tablets are oval-shaped with a distinctive blue coating composed of FD&C Blue #1 and Blue #2 aluminum lakes, ensuring identification and stability.
Packaging includes bottles with child-resistant caps and contains desiccant packets to maintain tablet integrity.
Inactive ingredients include colloidal silicon dioxide, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone K30, sodium lauryl sulfate, and sodium starch glycolate.
Tablet coatings additionally contain glyceryl monocaprylocaprate, partially hydrolyzed polyvinyl alcohol, talc, and titanium dioxide.
Nexlizet is supplied in bottles typically containing 30 or 90 tablets to support monthly or quarterly dosing regimens.
Storage recommendations specify room temperature between 20°C to 25°C (68°F to 77°F) in original packaging protected from moisture and heat.
Not formulated for pediatric use; specific adult dosing only.
Not available in generic formulations; only the brand-name combination product is marketed.
Used exclusively as a prescription medication with detailed prescribing information to guide clinical use.
Manufactured and distributed by Esperion Therapeutics, Inc.
The film coating facilitates swallowing and masks the bitter taste of active ingredients.
The preparation is designed for once-daily dosing to enhance patient adherence.
No injectable or topical formulations are available for this drug combination.
Compatible with co-administration with food; no special dietary considerations required for administration.